PharmTech Talk

FDA Advisors Unanimously Approve Sandoz Biosimilar

An FDA expert committee has recommend approval of Zarizio, the first US biosimilar application from Sandoz, setting a milestone for generic biologic drugs and setting the stage for future approvals.

 

More New Drugs and Faster Approvals

FDA set several milestones in approving more new, important drugs and biologics in 2014. Breakthrough drug designations went through through the roof, speeding more new therapies for cancer and critical conditions to patients.

source-image

Biosimilar Development Moves Forward at FDA

FDA has scheduled a public meeting in early January to assess and weigh data on the first United States application for a biosimilar therapy.

 

Achieving Long-Term Success in Supply-Chain Security

A global framework of standards enabling collaboration among industry stakeholders is needed to battle the increasing threat of counterfeit medicines.

source-image

Compassionate Use Debate Heats Up

Patient access to critical experimental medicines continues to grab public attention as states enact “Right-to-Try” laws and Congress eyes establishing a national policy to provide not-yet-approved therapies to terminally ill patients.

source-image

Ebola R&D Gets Big Boosts

The development and approval of new vaccines and antivirals to contain and treat the Ebola virus outbreak has become a top priority for the federal government and Congress, as seen in new policies to spur R&D and added funding for these efforts.

source-image

Taking a Closer Look into the Life-Science Funding Landscape in Europe and the United Kingdom

The author looks at how life-science research has evolved in Europe and the United Kingdom, and discusses the current funding opportunities for SMEs.

source-image

Breakthrough Successes Create Manufacturing Challenges

Sponsor response to FDA's breakthrough program has exceeded FDA expectations, but puts pressure on manufacturers to address formulation, stability and quality production issues very early in development.

source-image

New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy

The 2014 mid-term elections handed over control of the Senate to Republicans and boosted the GOP majority in the House, a clear blow to Obama administration policies, including the president’s landmark health reform initiative.

source-image

Combination Products Challenge Biopharma Manufacturers

Most new injectable drugs and biologics are being designed as combination therapies, presenting difficult regulatory and production issues for manufacturers.